Hi-Risk/Recurrent/Advanced PCa Video Chat, Jan 14, 2025

by | Jan 15, 2025 | Cancer Resources, High Risk/Recurrent/Advanced, High Risk/Recurrent/Advanced Prostate Cancer, mCRPC, mHSPC, nmCRPC, Prostate Cancer, Recorded Groups

Intermediate Risk Prostate Cancer Graphic

Hi-Risk/Recurrent/Advanced PCa Video Chat, Jan 14, 2025

It’s AnCan’s Annual Fundraiser – just once a year is the only time we ask for donations. FYI, we’ve received a mere 70 donations from this group, even though we have almost 300 regular participants, and 700 who receive the Reminder. Time to step up and show appreciation and gratitude if you watch these videos and find them helpful. Donate now at https://ancan.org/donate/

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostic.

If you missed any recent recordings, you’ll find a full list either on our YouTube Playlist or visit our Blog Post https://ancan.org/our-recent-blog-posts-in-case-you-missed-them/   Sign up for our Blog by checking the New Blog box at https://ancan.org/contact-us/
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime!
Join our other free and drop in groups:

 

Editor’s Pick: Without T, it’s not much of a drug holiday — dare he get shots? (bn)

 

Topics Discussed

From Rick: 33,000 views on AnCan YouTube channel – why you should consider an AnCan donation, if you haven’t – we’re digging into AnCan survey responses – a  cancer story that’s “a little eerie and pretty amazing”; 2-year drug holiday and still no testosterone — are testosterone shots a crazy idea? (lots of discussion on this); link between ADT and arithritis?; statin skeptic changes sides;  getting agonizing bone pain on a white blood cell stimulator —  Claritin might prevent it — better yet, see a palliative care doc; three Pluvicto treatments have driven his 200 PSA down to 1.7 — does he need more?; he’s got questons: why the bicalutamide – why no mutations in my somatic test? –  are drug holidays a whipsaw? – and what’s your average lifetime if you have prostate cancer?;  nine years into his illness, he offers a message of hope; can a biopsy show PSMA avidity?; after finishing Prolia, backing it up with bisphosphonates; reduction surgery for his ADT breasts — he loves the results; a runaround when he wants to watch his anemia, but the law’s on his side.

Chat Log

Luther · 6:39 PM
will do

AnCan  – rick · 6:39 PM
Patient Guide to BAT – Antonarakis & Denmeade   https://onlinelibrary.wiley.com/doi/full/10.1002/pros.24328#:~:text=BAT%20is%20a%20new%20treatment,the%20blood%20(Figure%203)

AnCan  – rick · 6:40 PM
Denmeade webinar on BAT https://ancan.org/bipolar-androgen-therapy-bat-sam-denmeade-md/

marc valens · 6:41 PM
see y’all next week. It’s time for my Telehealth with my GU Medonc Dr Aggarwal

AnCan  – rick · 6:42 PM
good luck

AnCan  – rick · 6:54 PM
single nucleotide polymorphism SNP

AnCan  – rick · 6:59 PM
Signatera  ctDNA test    https://www.natera.com/

AnCan  – rick · 7:00 PM
the Signatera test has not been cleared or approved by the FDA. However, the FDA has granted the Signatera molecular residual disease (MRD) test three Breakthrough Device Designations for use across multiple cancer types

AnCan  – rick · 7:01 PM
The test is available for clinical and research use and is covered by Medicare for patients with colorectal cancer, breast cancer, ovarian cancer and muscle invasive bladder cancer, as well as for immunotherapy monitoring of any solid tumor.Feb 26, 2024

AnCan  – rick · 7:02 PM
https://www.natera.com/company/news/medicare-extends-coverage-of-nateras-signatera-mrd-test-to-ovarian-cancer-and-neoadjuvant-breast-cancer/#:~:text=About%20Signatera&text=The%20test%20is%20available%20for,monitoring%20of%20any%20solid%20tumor.

AnCan  – rick · 7:56 PM
Usually a bisphosphonate infusion like Zometa – zoledronic acid